COMPANY
ABLi Therapeutics, Inc.
We are engineering Abl kinase inhibitors to treat Parkinson’s disease, Parkinson’s-related neurodegenerative diseases and other neurological diseases associated with Abl kinase dysfunction inside and outside of the brain. From company website Source · Oct 12, 2026
Funding and NIH signals
- SEC Form D raise Raised $1M (Form D filed Jan 13, 2026). SEC Form D 0002104142-26-000001 (Jan 13, 2026)
Evidence (1 event)
- Jan 13, 2026 · SEC Form D 0002104142-26-000001
Name of Issuer: ABLi Therapeutics, Inc.; CIK: 2104142; Address: Atlanta, GA; Submission type: D; Filing date: 2026-01-13; Industry Group: Pharmaceuticals; Date of First Sale: 2025-09-15; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 1000000; Total Amount Sold: 1000000; Federal exemptions: 06b
- Jan 13, 2026 · SEC Form D 0002104142-26-000001